BioSpace News Archive

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced enrollment of its first patient at one of its newest clinical sites, Columbia University New York-Presbyterian Hospital Irving Medical Center (“Columbia University”), in its ongoing TIGeR-PaC Phase 3 clinical trial.

Element Biosciences, Inc. today announced a key technical milestone using the Roche KAPA HyperPlus and KAPA EvoPlus library preparation and target enrichment kits in microbial whole genome, human whole genome, and human whole exome sequencing applications.

MedAvail Holdings, Inc. today announced the appointment of industry leaders Steven Hess to Executive Vice President, General Manager, of SpotRx and Bob McClune to Senior Vice President of Data and Analytics.

Moderna expects to enroll approximately 34,000 participants in multiple countries RSV causes severe disease burden among older adults and young children; there is no approved vaccine to prevent RSV.

Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases.

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 4th Annual Chronic Kidney Disease Drug Development (CKD) Summit in Boston from March 1 - 3, 2022.

Curebase, and CoBTeK, have announced a collaboration in the context of a cross-border (France & Italy) project in order to test the effectiveness of remote interventions in allowing elderly people to remain autonomous.

AbbVie today announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR®) to the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy.

The annual report highlights the significant efforts the company has made in advancing healthcare globally, increasing the diversity and engagement of its workforce, and reducing its global environmental footprint.

Exscientia announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO and Ben Taylor, CFO & Chief Strategy Officer, will participate in fireside chats at the following investor conferences in March: